Cardiff Oncology, Inc. Common Stock CRDF
Key Stats
- Today's Range
- $0.93 – $0.97
- 50-Day Range
- $0.76 – $1.98
- 52-Week Range
- $0.76 – $4.55
- Volume
- 446K shs
- Average Volume
- 1.64 million shs
- Market Cap
- $74.71 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.17%
- Days to Cover
- 1.64
About Cardiff Oncology, Inc. Common Stock
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
Related Stocks
Compare head-to-head: CRDF vs AMGN·CRDF vs HALO·CRDF vs RGEN·CRDF vs IMVT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.